Article -> Article Details

Market approval depends on proving that a generic tablet manufacturer's product performs identically to the brand-name reference. Unlike innovator drugs, generics do not need to undergo expensive clinical trials; instead, they must demonstrate bioequivalence, showing that the generic delivers the same active ingredient into the bloodstream at the same rate and extent as the reference product.

This streamlined approach has established generic drugs as a foundational element of contemporary healthcare, constituting over 90% of prescriptions in the U.S. However, the term "abbreviated" does not imply ease, as the bioequivalence standards for generic tablets are stringent, detailed, and continually changing.

Ø  Understanding Bioequivalence:

A bioequivalence study assesses the pharmacokinetic properties of a reference drug and its generic alternative to ensure they perform similarly in the body. Regulatory agencies like the FDA, EMA, and WHO mandate these studies for generic drug approval to confirm safety, efficacy, and interchangeability with the branded product.

To implement bioequivalence, pharmacokinetic studies measure three key parameters.

Cmax and AUC are key indicators of bioequivalence, offering measurable insights into a drug's behavior in the body.

Ø  The 80/125 Regulatory Standard

To establish that a generic product satisfies regulatory standards, pharmacokinetic data must undergo a bioequivalence (BE) assessment using the two-one-sided test (TOST) procedure. This method confirms bioequivalence by ensuring that the 90% confidence interval for the key pharmacokinetic parameters (Cmax and AUC) of the test product relative to the reference product falls within the regulatory limits of 80.00% to 125.00%.

Ø  ICH M13A Changes

A significant change took place in January 2025 with the adoption of the ICH M13A guideline, which standardizes bioequivalence for immediate-release solid oral dosage forms globally, being accepted by both the FDA and EMA.

Key Benefits of ICH M13A:

 Single Study Instead of Dual Fasting/Fed Studies

Manufacturers of oral tablets and capsules now require only one bioequivalence study, streamlining development and reducing clinical study costs.

Global Harmonization

ICH M13A standardizes bioequivalence (BE) study requirements across ICH regions, including the US, EU, and Canada, thereby reducing regulatory and development redundancies.

Structured Framework

The guidance outlines detailed recommendations for study design, analytical methodologies, and statistical approaches in line with local and global regulatory standards.

Why Bioequivalence Matters

 Bioequivalence testing is not merely a regulatory hurdle—it serves several critical purposes:

•  Ensures therapeutic consistency, meaning patients receive the same clinical benefits from both generic and brand-name drugs.
• BE testing accelerates generic drug approval by reducing the need for extensive clinical trials, thereby lowering costs and enhancing market availability.
•    Generic medications must meet BE criteria to be substituted for brand-name drugs; otherwise, prescriber approval is required.
•  BE studies enhance drug affordability by ensuring generics perform similarly to branded medications, providing patients with more cost-effective options.

Ø  Challenges in Bioequivalence Studies

Oral solid dosage forms, though labeled as "simple" generics, pose considerable challenges.

  Highly Variable Drugs (HVDs)

For drugs exhibiting high within-subject variability (≥30% CV), the conventional 80–125% confidence interval may be overly conservative, potentially leading to the rejection of truly equivalent generics because of biological noise. To address this, the FDA has implemented the Reference-Scaled Average Bioequivalence (RSABE) methodology, which modifies bioequivalence acceptance limits based on the variability of the reference product.

Narrow Therapeutic Index (NTI) Drugs

NTI drugs face stricter bioequivalence standards due to the risk of serious therapeutic failures or adverse reactions from minor dosage changes, necessitating tighter limits and replicate study designs.

 Formulation Sensitivities

Differences in excipients, manufacturing processes, or particle size can significantly affect dissolution and absorption profiles, which may impact bioequivalence outcomes.

Navigating bioequivalence studies and ICH M13A requirements requires expertise, and CurexBio offers comprehensive services to help generic manufacturers achieve regulatory approval efficiently and with confidence.

1. 
   

   Bioanalytical Services

Bioanalytical testing is crucial for bioequivalence studies and regulatory submissions. CurexBio provides a variety of services, including bioanalytical method development, method validation, sample analysis, pharmacokinetic evaluations, and biomarker analysis.

2. 
   

   Clinical Monitoring Services

BE studies at CurexBio involve ongoing oversight for compliance with GCP, ensuring site compliance, source data verification, protocol adherence, patient safety, and inspection readiness through comprehensive clinical monitoring.

3. 
   

   Biostatistics and PK/PD Analysis

Statistical evaluation is crucial for showing bioequivalence, supported by CurexBio, which offers services including statistical analysis plans, PK/PD analysis, bioequivalence calculations, data interpretation, and regulatory statistical reporting.

4. 
   

   Clinical Data Management

Accurate data collection and management are essential for successful submissions. CurexBio's clinical data management system supports sponsors by ensuring data integrity, validating databases, managing queries, cleaning data, and maintaining regulatory compliance.

5. 
   

   Medical Writing Services

Regulatory authorities mandate extensive documentation, which our team addresses through its medical writing services. These services encompass clinical study protocols, clinical study reports, investigator brochures, regulatory summaries, and submission documents.

6. 
   

   Regulatory Affairs Services

CurexBio aids in regulatory strategy development, submission preparation, gap assessments, agency response management, and lifecycle maintenance.

CurexBio offers essential bioanalytical, clinical, statistical, and regulatory support to generic manufacturers, facilitating bioequivalence studies and regulatory submissions, thereby accelerating the approval of affordable generic medicines for patients.

Ready to advance your generic tablet through bioequivalence testing? Contact CurexBio to learn about our BE study services for ANDA submission.